Foghorn Therapeutics Inc. (FHTX) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs Transcript

Core Viewpoint - The conference call focuses on Foghorn's proprietary programs, particularly the selective ARID1B degrader, along with updates on other programs like selective CBP and EP300 degraders [2][4]. Group 1: Company Overview - Karin Hellsvik, Vice President of Investor Relations and Corporate Affairs, leads the call and emphasizes the focus on Foghorn's selective ARID1B degrader and other proprietary programs [2]. - Adrian Gottschalk, President and CEO, will provide an overview of the company's recent progress [4]. Group 2: Pipeline Updates - The call will include updates on the progress of Foghorn's proprietary pipeline programs, specifically ARID1B, CBP, and EP300, along with new data presented [4].